|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
This study underlines the importance of the EGFR ligand, Amphiregulin, as a key mediator of estrogen receptor action in breast cancer.
|
31838731 |
2020 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The resistance to the endocrine therapy of breast cancer leads to the emergence of new class of drugs that downregulates the estrogen receptor action known as selective estrogen receptor downregulators (SERDs).
|
31038398 |
2020 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The absence of ER in breast cancer before and after NAC would be a significant prognostic factor for local recurrence and distant metastasis.
|
31204155 |
2020 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The risk of SPM was significantly related to the following demographical and clinical variables: age (40-59 vs. 18-39, HR = 1.33; 60-79 vs. 18-39, HR = 2.39; ≥80 vs. 18-39, HR = 2.84), race (black vs. white, HR = 1.12), histological type (lobular BC vs. ductal BC, HR = 1.15), radiotherapy (HR = 1.33), marital status (married vs. single, HR = 0.88) and estrogen receptor status (positive vs. negative, HR = 0.85).
|
30861567 |
2020 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
To investigate possible associations between quantitative apparent diffusion coefficient (ADC) metrics derived from whole-lesion histogram analysis and breast cancer recurrence risk in women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-negative breast cancer who underwent the Oncotype DX assay.
|
31385051 |
2020 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The clinical efficacy of new HER2-targeting antibody-drug conjugates needs to be validated in this high-risk subset of ER+ breast cancer patients.
|
31811505 |
2020 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The cure rate of patients with ERα-positive breast cancer is, however, limited due to the occurrence of endocrine resistance.
|
31701491 |
2020 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Prospective cohort studies of Cd and breast cancer risk suggest a significant relationship between increased Cd intake and cancer incidence, with more pronounced effects for estrogen receptor α (ERα)-positive breast cancers.
|
31689473 |
2020 |
|
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The expression of carbonic anhydrase XII (CA12) is associated with the expression of estrogen receptor alpha (ERα) in breast cancer and is linked to a good prognosis with a lower risk of metastasis.
|
31636386 |
2020 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In this study, due to the overexpression of the estrogen receptor (ER) in breast cancer and the ability of ER to specifically bind to its ligand estrone (ES), an ES-targeted PEGylated epirubicin (EPI) and paclitaxel (PTX) co-loaded liposomal nanoparticle (NP) (termed as ES-SSL-EPI/PTX) was developed.
|
31678519 |
2020 |
|
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated the relationships of pathological response after neoadjuvant chemo-endocrine therapy with alterations in the Ki67 labeling index (LI), expression of cyclin D1 (CCND1) and progesterone receptor (PgR), and estrogen receptor (ER) activity in breast cancer.
|
31112577 |
2019 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Estrogen receptor α (ERα) is a key regulator of breast cancer.
|
30399599 |
2019 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In estrogen receptor‑positive [ER(+)] breast cancer patients, aberrant α‑SMA expression was found to be associated with a poor prognosis.
|
30535478 |
2019 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
These results reveal a direct role of MIR2052HG in LMTK3 regulation and raise the possibilities of targeting MIR2052HG or LMTK3 in ERα-positive breast cancer.
|
30944027 |
2019 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In addition, STC2 gene probably promotes the development and metastasis of breast cancer by interacting with estrogen and ER, and it may become a new direction for breast cancer endocrine therapy.
|
31845230 |
2019 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Stratified analyses showed that genetically predicted fasting insulin was more closely related to risk of estrogen-receptor [ER]-positive cancer, whereas the associations with instruments of 2-h glucose, BMI and WHRadj BMI were consistent regardless of age, menopausal status, estrogen receptor status and family history of breast cancer.
|
30277539 |
2019 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
This is the first report showing that BC exosomes contain MTA1 and can transfer it to other cells resulting in changes to hypoxia and estrogen receptor signaling in the tumor microenvironment.
|
30782165 |
2019 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Antiestrogens (AEs) are widely used for treatment of estrogen receptor alpha (ERα)-positive breast cancer, but display variable degrees of partial agonism in estrogen target tissues and breast cancer (BC) cells.
|
30190545 |
2019 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Finally, we show that depletion of both KDM3A and KDM4B has a greater inhibitory effect on ER activity and cell growth than knockdown of each individual enzyme, suggesting that targeting both enzymes represents a potentially efficacious therapeutic option for ER-driven breast cancer.
|
31390833 |
2019 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The purpose of this research was to analyse the potential roles of AR, PDEF and ERα levels in the response to tamoxifen resistance in ERα-positive BC.
|
31297554 |
2019 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Expression of MDM2 and MDMX occurs in estrogen receptor α-positive (ERα<sup>+</sup>) breast cancer and triple-negative breast cancer (TNBC).
|
30642351 |
2019 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Intraductal patient-derived xenografts of estrogen receptor α-positive breast cancer recapitulate the histopathological spectrum and metastatic potential of human lesions.
|
30430577 |
2019 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We assessed proliferation, cell cycle, and migration of breast cancer cells (estrogen receptor (ER)-positive: MCF-7 and ER-negative: MDA-MB-231) treated with BPF and BPS ± estrogen receptor inhibitor (ERI) in comparison to BPA ± ERI.
|
31601247 |
2019 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Here, by studying two additional LAM cohorts with more detailed epidemiological, life-style, and disease-related data, we show consistent results; a potential excess of estrogen-receptor-positive young breast cancer cases in LAM.
|
31260937 |
2019 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Cytochrome c1 as a favorable prognostic marker in estrogen receptor-positive breast carcinoma.
|
31149728 |
2019 |